Soligenix sets up consortium to develop thermostable vaccines

Soligenix of the US, formerly known as DOR BioPharma, has established a consortium to develop thermostable technology to advance its RiVax vaccine and other rapidly acting vaccines. The consortium will be funded by a $9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the US National Institutes of Health (NIH).

Soligenix of the US, formerly known as DOR BioPharma, has established a consortium to develop thermostable technology to advance its RiVax vaccine and other rapidly acting vaccines. The consortium will be funded by a $9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the US National Institutes of Health (NIH).

The consortium will consist of partnerships between industry and academic researchers from different disciplines. Academic institutions participating include the University...

More from Immunological

More from Therapeutic Category

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.

Insmed’s New R&D Site Focused On ‘Synthetic Rescue’

 

A new small-molecule approach to turning on beneficial genes to counteract disease-causing mutations is being pioneered by Insmed’s UK-based scientists.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?